An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer

Roche

Status: Completed

Conditions: Colorectal Cancer

Treatments: Biological: Oxaliplatin; Drug: Capecitabine

Study type: Observational

Funder types: Industry

Identifiers

NCT01442155

ML25526

Details and patient eligibility

About

This observational study evaluates the efficacy and safety of capecitabine in combination with oxaliplatin in the adjuvant setting in participants with Stage III colon cancer. Data were collected from each participant for up to 36 months or until disease recurrence.

Enrollment: 74 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult participants, >/= 18 years of age
• Treatment in line with the currently approved indication in the Summary of Product Characteristics

Exclusion criteria

• Contraindications according to the current Summary of Product Characteristics

Trial design

74 participants in 1 patient group

Capecitabine + Oxaliplatin

Description:

Participants with stage lll colon cancer, who were starting adjuvant chemotherapy with capecitabine in combination with oxaliplatin according to standard of care.

Treatment:

Biological: Oxaliplatin

Drug: Capecitabine